Clinical significance of cytomegalovirus viremia in bone marrow transplantation.
Cytomegalovirus (CMV) viremia was systematically studied in 56 patients having undergone bone marrow transplantation for leukemia or aplastic anemia. Of the patients who survived at least three months, 57% had CMV viremia with a frequency peak between the 7th and the 9th weeks. We describe possible clinical signs associated with viremia, particularly late peripheral and/or central thrombocytopenia. The occurrence of viremia was studied according to the specific preexisting immune status of recipients and donors; granulocyte transfusions and graft-versus-host disease. The relationship between these parameters and viremia provides a basis for the analysis of prophylactic treatments of CMV infection.
Vilmer
E
E
Mazeron
M C
MC
Rabian
C
C
Azogui
O
O
Devergie
A
A
Perol
Y
Y
Gluckman
E
E
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002472:Cell Transformation, Viral; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000097:blood / Q000209:etiology* / Q000276:immunology; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D014184:Transplantation, Homologous / Q000009:adverse effects; D014766:Viremia / Q000097:blood / Q000209:etiology* / Q000276:immunology